GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Olema Pharmaceuticals inc (NAS:OLMA) » Definitions » Enterprise Value

Olema Pharmaceuticals (Olema Pharmaceuticals) Enterprise Value : $296.96 Mil (As of Apr. 28, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Olema Pharmaceuticals Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Olema Pharmaceuticals's Enterprise Value is $296.96 Mil. Olema Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-104.96 Mil. Therefore, Olema Pharmaceuticals's EV-to-EBIT ratio for today is -2.83.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Olema Pharmaceuticals's Enterprise Value is $296.96 Mil. Olema Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-104.58 Mil. Therefore, Olema Pharmaceuticals's EV-to-EBITDA ratio for today is -2.84.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Olema Pharmaceuticals's Enterprise Value is $296.96 Mil. Olema Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Olema Pharmaceuticals's EV-to-Revenue ratio for today is .


Olema Pharmaceuticals Enterprise Value Historical Data

The historical data trend for Olema Pharmaceuticals's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Olema Pharmaceuticals Enterprise Value Chart

Olema Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial - 1,551.39 88.54 -103.15 512.16

Olema Pharmaceuticals Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -103.15 -43.34 205.90 400.05 512.16

Competitive Comparison of Olema Pharmaceuticals's Enterprise Value

For the Biotechnology subindustry, Olema Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Olema Pharmaceuticals's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Olema Pharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Olema Pharmaceuticals's Enterprise Value falls into.



Olema Pharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Olema Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Olema Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Olema Pharmaceuticals  (NAS:OLMA) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Olema Pharmaceuticals's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=296.962/-104.961
=-2.83

Olema Pharmaceuticals's current Enterprise Value is $296.96 Mil.
Olema Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-104.96 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Olema Pharmaceuticals's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=296.962/-104.584
=-2.84

Olema Pharmaceuticals's current Enterprise Value is $296.96 Mil.
Olema Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-104.58 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Olema Pharmaceuticals's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=296.962/0
=

Olema Pharmaceuticals's current Enterprise Value is $296.96 Mil.
Olema Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Olema Pharmaceuticals Enterprise Value Related Terms

Thank you for viewing the detailed overview of Olema Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Olema Pharmaceuticals (Olema Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
512, 2nd Street, 4th Floor, San Francisco, CA, USA, 94107
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.
Executives
Cyrus Harmon director, officer: Chief Technology Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Paradigm Biocapital Advisors Lp 10 percent owner 767 THIRD AVENUE, 17TH FLOOR, NEW YORK NY 10017
G. Walmsley Graham director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kovacs Shane William Charles officer: Ch. Operating & Financial Off. PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Naseem Zojwalla officer: Chief Medical Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Sean Bohen director, officer: President and CEO C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
David C. Myles officer: Chief Development Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Senai Asefaw 10 percent owner 767 THIRD AVENUE, 17TH FLOOR, NEW YORK CITY NY 10017
Paradigm Biocapital International Fund Ltd. 10 percent owner C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Biotechnology Value Fund L P 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Paradigm Biocapital Advisors Gp Llc 10 percent owner 767 THIRD AVENUE, 17TH FLOOR, NEW YORK CITY NY 10017
Kinney Horn officer: Chief Business Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Yi Larson director C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116